NewBiologix and Synastra Biotechnology announced a manufacturing agreement to advance rAAV production for Synastra’s investigational Duchenne muscular dystrophy (DMD) gene therapy program. The collaboration centers on building and characterizing a research cell bank for a stable producer cell line using NewBiologix’s Xcell platform.